1500 East Medical Center Drive
Ann Arbor, MI 48109
Available to mentor
Anna Suk-Fong Lok, M.D., is director of clinical hepatology and assistant dean for clinical research at the University of Michigan Medical School. She also is the Dame Sheila Sherlock Distinguished University Professor of Hepatology and Internal Medicine and Alice Lohrman Andrews Research Professor of Hepatology in the Department of Internal Medicine.
In her role as assistant dean, Dr. Lok is responsible for leading, championing, and implementing recommendations from the Research Board of Directors to transform the clinical trials enterprise of the academic medical center. She is responsible for the overall leadership and direction, management, and oversight of the Clinical Trials Support Units and the Clinical Research Unit, training of clinical investigators, and facilitation and support of clinical research.
Dr. Lok obtained her medical degree from the University of Hong Kong and her hepatology training under the late Dame Sheila Sherlock at the Royal Free Hospital in London, UK. She was on the faculty at the University of Hong Kong until she moved to the United States in 1992.
Her research focuses on the natural history and treatment of hepatitis B and C, and the prevention of liver cancer. Her research is funded by the National Institutes of Health, federal and private foundations, and various pharmaceutical companies. She has published more than 600 papers on viral hepatitis and liver diseases and is the co-author of five editions of the American Association for the Study of Liver Diseases Association Guidelines on Hepatitis B. She was one of the top 1% most cited scientists in the world for the decade 2002-12. She has trained more than 60 fellows and junior faculty from all over the world, some of whom have risen to the ranks of full professors and directors of liver programs in their home country. She received a Distinguished Mentor Award from the Michigan Institute of Clinical and Health Research in 2012, an Inspirational Physician Award from the American Medical Association in 2014, and a Distinguished Mentor Award from the American Gastroenterological Association in 2022. She was inducted into the Clinical Excellence Society in the Department of Internal Medicine in 2013.
Dr. Lok has received many awards throughout her career. She has been included in the list of “Best Doctors” and “Who's Who” for many years. She was inducted into the Association of American Physicians in 2012 and elected to the National Academy of Medicine in 2022. Recent awards include the Distinguished Scientist Award from the Hepatitis B Foundation in 2008, the Distinguished Women Scientist Award from the American Gastroenterological Association in 2008, the Distinguished Service Award from the American Association for the Study of Liver Diseases in 2011, the Distinguished Scientific Achievement Award from the American Liver Foundation in 2015, the William Beaumont Prize in Gastroenterology from the American Gastroenterological Association in 2016, a Gold Medal Award from the Canadian Association for the Study of the Liver and an honorary Doctor of Science degree from the University of Hong Kong in 2017, the International Recognition Award from the European Association of the Study of the Liver in 2018, and a Distinguished University Professorship from the University of Michigan in 2019.
She is currently an associate editor of Hepatology Communication. She was an associate editor of HEPATOLOGY from 2001-06, a co-editor of the Journal of Viral Hepatitis from 2007-09, and a senior associate editor of GASTROENTEROLOGY from 2011-12.
Dr. Lok was the President of the American Association for the Study of Liver Diseases in 2017.
-
MDUniversity of Hong Kong, Hong Kong, 1990
-
MB BSUniversity of Hong Kong School of Medicine, Hong Kong, 1977
-
Center MemberMM-PKUHSC Joint Institute
-
Center MemberRogel Cancer Center
-
Center MemberGlobal REACH
-
Center MemberInstitute for Healthcare Policy and Innovation
Epidemiology, natural history, and treatment of hepatitis B and C
Risk stratification of nonalcoholic fatty liver disease
Prevention and early detection of hepatocellular carcinoma
-
Malespin MH, Barritt AS, Watkins SE, Schoen C, Tincopa MA, Corbin KD, Mospan AR, Munoz B, Trinh HN, Weiss LM, Reddy KR, Loomba R, Kemmer N, Lok AS. Clin Gastroenterol Hepatol, 2022 Oct; 20 (10): 2393 - 2395.e4.Journal ArticleWeight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort.
DOI:10.1016/j.cgh.2021.01.023 PMID: 33486083 -
Reeve BB, Michael L, Peter JA, Stewart PW, Lok AS-F, Dong M, Bergquist K, Nelson DR, Evon DM. GastroHep, 2022 Jul 4; 2022 (1): 1 - 9.Journal ArticleConcordance between Patients and Clinicians for Reporting Symptoms Associated with Treatment for Chronic Hepatitis C during a Pragmatic Clinical Trial
DOI:10.1155/2022/2673911 -
DiBattista JV, Lok A, Chen VL. Gastroenterology, 2022 May; 162 (7): s-1291-s-1292Journal ArticleEP1222: SHORT-TERM WEIGHT LOSS ONLY OCCURS IN 25% OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE BUT IS ASSOCIATED WITH SUSTAINED WEIGHT LOSS AND DECREASED ALANINE AMINOTRANSFERASE
DOI:10.1016/s0016-5085(22)63783-1 -
Tincopa MA, Lyden A, Wong J, Jackson EA, Richardson C, Lok AS. Dig Dis Sci, 2022 Feb; 67 (2): 481 - 491.Journal ArticleImpact of a Pilot Structured Mobile Technology Based Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease.
DOI:10.1007/s10620-021-06922-6 PMID: 33939147 -
Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Clin Gastroenterol Hepatol, 2022 Jan; 20 (1): 9 - 18.Journal ArticleConceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda.
DOI:10.1016/j.cgh.2020.09.036 PMID: 32961340 -
Sulkowski MS, Moon JS, Sherman KE, Morelli G, Darling JM, Muir AJ, Khalili M, Fishbein DA, Hinestrosa F, Shiffman ML, Di Bisceglie A, Rajender Reddy K, Pearlman B, Lok AS, Fried MW, Stewart PW, Peter J, Wadsworth S, Kixmiller S, Sloan A, Vainorius M, Horne PM, Michael L, Dong M, Evon DM, Segal JB, Nelson DR, PRIORITIZE Study Team . Hepatology, 2021 Dec; 74 (6): 2952 - 2964.Journal ArticleA Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
DOI:10.1002/hep.32053 PMID: 34255381 -
Mellinger JL, Winder GS, Fernandez AC, Klevering K, Johnson A, Asefah H, Figueroa M, Buchanan J, Blow F, Lok ASF. J Subst Abuse Treat, 2021 Nov; 130: 108396Journal ArticleFeasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic.
DOI:10.1016/j.jsat.2021.108396 PMID: 34118717 -
Ghany MG, Lok ASF, Dienstag JL, Feinstone SM, Hoofnagle JH, Jake Liang T, Seeff LB, Cohen DE, Bezerra JA, Chung RT. Hepatology, 2021 Nov; 74 (5): 2813 - 2823.Journal ArticleThe 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence.
DOI:10.1002/hep.31830 PMID: 33784424